Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
  • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/06—Fungi, e.g. yeasts
  • A61K36/062—Ascomycota
  • A61K36/064—Saccharomycetales, e.g. baker's yeast
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/20—Interleukins [IL]
  • A61K38/204—IL-6
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/20—Interleukins [IL]
  • A61K38/2066—IL-10
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/54—Interleukins [IL]
  • C07K14/5428—IL-10
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K16/241—Tumor Necrosis Factors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/70—Vectors or expression systems specially adapted for E. coli
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Definitions

• Some aspects of the present disclosure relate to the field of biosynthetic engineering.
• Some aspects of the present disclosure relate to the methods and compositions for the diagnosis and treatment of inflammatory bowel disease.
• IBD Inflammatory bowel disease
• IBD Crohn's disease and ulcerative colitis.
• current IBD therapies involve high, general dosing of anti-inflammatory agents that can lead to severe side effects, such as immunodeficiency. It is also challenging to detect early disease flares in a non-invasive fashion, thus making it difficult to treat the disease in patients before symptoms become severe.
• new technologies are needed to improve the study of IBD in animal models, to enable early detection of disease flares, and to achieve targeted delivery of anti-inflammatory therapies.
• the disclosure relates to a recombinant probiotic cell comprising a sensor circuit, comprising: (a) a first promoter operably linked to a nucleic acid encoding a regulatory protein responsive to an input signal; (b) a second promoter responsive to the regulatory protein and operably linked to a nucleic acid encoding a first output protein, wherein activity of the second promoter is altered when bound by the regulatory protein; (c) an output molecule operably linked to a third promoter, wherein the output molecule or the third promoter is flanked by a first set of regulatory sequences, wherein the first set of regulatory sequences interacts with the first output protein to unlink the output molecule from the third promoter; (d) a fourth promoter responsive to the regulatory protein and operably linked to a nucleic acid encoding a second output protein, wherein activity of the fourth promoter is altered when bound by the regulatory protein; and, optionally, (e) a second output molecule flanked by a second set of regulatory sequence
• the promoter of (a) is a con stitutively- active promoter.
• the regulatory protein is selected from the group consisting of oxyR, NorR, and NsrR.
• the input signal is hydrogen peroxide (H 2 O 2 ).
• the input signal is nitric oxide (NO).
• the input signal is an inflammatory cytokine, optionally IL-6, IL-18, or TNFa.
• the input molecule is a molecule produced by neutrophils, such as calprotectin or lactoferrin.
• the input signal is blood.
• the promoter of (b) and/or (d) comprises a modification that alters the binding affinity of a transcription factor or RNA polymerase for the promoter of (b) and/or (d), relative to a similar unmodified promoter.
• the promoter of (b) and/or (d) comprises a modification that alters the binding affinity of a transcription factor or RNA polymerase for the promoter of (b) and/or (d), relative to a similar unmodified promoter.
• (a), (b) and (c) as described above are on a vector. In some embodiments, (a), (b), (c) and (d) as described above are on a vector. In some embodiments, (a) and (b) are on a single vector. In some embodiments, (a), (b) and (d) are on a single vector. In some embodiments, (c) and/or (e) is on a bacterial artificial chromosome (BAC).
• BAC bacterial artificial chromosome
• (b) and/or (d) further comprises a sequence element that regulates production of the first output protein and is located between the second promoter and the nucleic acid encoding the first output protein.
• the sequence element regulates transcription or translation of the output protein.
• the sequence element is a ribosomal binding site.
• the sequence element is a modified ribosomal binding site comprising a modification that alters the binding affinity of a ribosome for the modified ribosomal binding site, relative to a similar unmodified ribosomal binding site.
• the promoter of (b) and/or (d) is a promoter selected from the group consisting of oxyR, katGp oxySp, ahpSp, HemHp, ahpCp2, dsbGp, uofp, dpsp, grxAp, ybjCp, hcpp, ychFp, sufAp, flup, mntHp, trxCp, gorp, yhjAp, oxyRp, gntPp, uxuAp, fhuFp, katGp, nir, hep, nrf A, nasD, ytfE, yeaR, nnrS and norV that comprises a modification that alters the binding affinity of a transcription factor or RNA polymerase for a promoter selected from the group consisting of oxyR, katGp oxySp, a
• the promoter of (b) and/or (d) is a promoter selected from the group consisting of oxyR, katGp oxySp, ahpSp, HemHp, ahpCp2, dsbGp, uofp, dpsp, grxAp, ybjCp, hcpp, ychFp, sufAp, flup, mntHp, trxCp, gorp, yhjAp, oxyRp, gntPp, uxuAp, fhuFp, katGp, nir, hep, nrfA, nasD, ytfE, yeaR, nnrS and norV that is a naturally occurring promoter.
• the first output protein of (b) is a recombinase and the first set of regulatory sequences of (c) is recombinase recognition sites.
• the second output protein of (d) is a recombinase and the second set of regulatory sequences of (e) is recombinase recognition sites.
• the first output molecule and/or the second output molecule is detectable. In some embodiments, the first output molecule and/or the second output molecule is detectable by PCR, DNA sequencing or microscopy, optionally fluorescent microscopy.
• the first output molecule and/or the second output molecule is a therapeutic molecule. In some embodiments, the first output molecule and the second output molecule are the same molecule. In some embodiments, the therapeutic molecule is an anti-inflammatory molecule. In some embodiments, the anti-inflammatory molecule is a cytokine, optionally IL-10. In some embodiments, the anti-inflammatory molecule is curcumin.
• the cell is a bacterial cell or a fungal cell. In some embodiments, the cell is a bacterial cell or a fungal cell. In some
• the bacterial cell is an E. coli cell, optionally an E. coli Nissle 1917 cell.
• the fungal cell is a yeast cell, optionally, a Saccharomyces boulardii cell.
• the disclosure relates to a method of treating an inflammatory bowel disease in a subject in need thereof, the method comprising administering to a subject in need thereof a probiotic cell as described herein.
• the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
• the sensor circuit is a biological analog signal processing circuit.
• the input signal is hydrogen peroxide (H 2 O 2 ).
• the input signal is nitric oxide (NO).
• the input molecule is an inflammatory cytokine, optionally IL-6, IL-18, or TNFa.
• the input molecule is a molecule produced by neutrophils, such as calprotectin or lactoferrin.
• the input signal is blood.
• the first and/or second output molecule is detectable. In some embodiments of the method, the first and/or second output molecule is detectable by PCR, DNA sequencing or microscopy, optionally fluorescent microscopy. In some embodiments of the method, the output molecule is detectable via colorimetric observations.
• the first and/or second output molecule is a therapeutic molecule.
• the therapeutic molecule is an anti-inflammatory molecule.
• the anti-inflammatory molecule is a cytokine, optionally IL-10.
• the antiinflammatory molecule is curcumin.
• the antiinflammatory molecule is an antibody or antibody fragment.
• the sensor circuit further comprises a second output molecule.
• the second output molecule is the same as the first output molecule.
• the disclosure relates to a method of diagnosing an inflammatory bowel disease in a subject, the method comprising: a) administering to a subject a probiotic cell as described herein; b) obtaining a biological sample from the subject of (a); c) detecting the expression of the at least one output molecule in the biological sample; and, d) diagnosing the subject as having an inflammatory bowel disease.
• the probiotic cell colonizes the intestinal tract.
• the subject is a mammal.
• the subject is a human.
• the biological sample is a fecal sample.
• the expression of the output molecule is detected in vitro.
• the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
• the method further comprises administering an agent useful for treatment of IBD to the subject.
• recombinant probiotic cells include a sensor circuit that includes (a) a first promoter operably linked to a nucleic acid encoding a regulatory protein responsive to an input signal; and (b) a second promoter responsive to the regulatory protein and operably linked to a nucleic acid encoding a first output protein, wherein activity of the second promoter is altered when bound by the regulatory protein.
• the first promoter is a constitutively-active promoter.
• the regulatory protein is selected from the group consisting of oxyR, NorR, and NsrR.
• the input signal is hydrogen peroxide
• the input signal is nitric oxide (NO).
• the input signal is an inflammatory cytokine, optionally IL-6, IL-18, or TNFa.
• the second promoter includes a modification that alters the binding affinity of a transcription factor or RNA polymerase for the second promoter, relative to a similar unmodified promoter.
• the modification is a nucleic acid mutation.
• (a) and (b) are on a vector, in some embodiments, on a single vector.
• (b) further includes a sequence element that regulates production of the first output protein and is located between the second promoter and the nucleic acid encoding the first output protein. In some embodiments, the sequence element regulates transcription or translation of the output protein. In some embodiments, the sequence element is a ribosomal binding site. In some embodiments, the sequence element is a modified ribosomal binding site comprising a modification that alters the binding affinity of a ribosome for the modified ribosomal binding site, relative to a similar unmodified ribosomal binding site.
• the promoter of (b) is a promoter selected from the group consisting of oxyR, oxySp, katGp, nir, hep, nrfA, nasD, ytfE, yeaR, nnrS and norV that comprises a modification that alters the binding affinity of a transcription factor or RNA polymerase for a promoter selected from the group consisting of oxyR, nir, hep, nrfA, nasD, ytfE, yeaR, nnrS and norV of (b), relative to a similar unmodified promoter.
• the promoter of (b) is a promoter selected from the group consisting of oxyR, oxySp, katGp, nir, hep, nrfA, nasD, ytfE, yeaR, nnrS and norV that is a naturally occurring promoter.
• the first output molecule is a therapeutic molecule.
• the therapeutic molecule is an anti-inflammatory molecule.
• the anti-inflammatory molecule is a cytokine, optionally IL- 10.
• the anti-inflammatory molecule is curcuminoid synthase
• the recombinant probiotic cell further includes nucleic acids that encode 4-coumarate : CoA ligase and acetyl- CoA carboxylase which nucleic acids optionally are on one or more vectors.
• the nucleic acids that encode acetyl-CoA carboxylase are AccBc and DtsRl.
• nucleic acids that encode 4-coumarate : CoA ligase and acetyl-CoA carboxylase are operably linked to constitutive promoters.
• the cell is a bacterial cell or a fungal cell. In some embodiments, the cell is a bacterial cell or a fungal cell. In some
• the bacterial cell is an E. coli cell, optionally an E. coli Nissle 1917 cell.
• the fungal cell is a yeast cell, optionally, a Saccharomyces boulardii cell.
• methods of treating an inflammatory bowel disease in a subject in need thereof include administering to a subject in need thereof the foregoing probiotic cell that include a sensor circuit that includes (a) a first promoter operably linked to a nucleic acid encoding a regulatory protein responsive to an input signal; and (b) a second promoter responsive to the regulatory protein and operably linked to a nucleic acid encoding a first output protein, wherein activity of the second promoter is altered when bound by the regulatory protein.
• the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
• Figs. 1A-1D provide an overview of engineered probiotics for sensing-and-treating inflammation.
• Fig. 1A shows probiotic cells (for example, E. coli) pass through the gut and encounter sites of inflammation (squares and "X").
• Fig. IB shows the design of probiotic cells engineered to sense and memorize the presence and concentration of inflammatory markers (dots), thus enabling early detection of inflammation (light shaded cells, right).
• Fig. 1C shows the design of probiotic cells that constitutively synthesize anti-inflammatory molecules (circles).
• Fig. ID shows the design of targeted therapies for IBD via probiotic cells that can sense inflammation (squares, "X”) and respond by locally secreting anti- inflammatory therapies (circles).
• Figs. 2A-2C show a schematic for engineered inflammation- sensing circuits with integrated memory based on DNA recombinases.
• Fig. 2A shows a schematic demonstrating the expression of three different DNA recombinases (Rec. 1, 2, 3) is induced at different levels of inflammatory molecules, such as ⁇ 2 0 2 and NO.
• Fig. 2B shows that upon expression, each DNA recombinase (Rl, R2, R3) shown in Fig. 2A inverts an independent output DNA sequence, thus resulting in permanent expression of a separate output gene contained within the inverted sequence (Output 1, Output 2, Output 3, respectively).
• These output genes can include detectable reporters, as well as therapeutic proteins or small- molecule biosynthetic genes.
• Fig. 2C shows a schematic representation of the response of the engineered probiotic cells to an inflammatory marker. Multiple output genes are expressed depending on the level of inflammation that has been encountered. For example, inflammation levels that are between Threshold 1 and Threshold 2 would only induce the Output 1 (left curve), but inflammation levels above Threshold 3 would induce Output 1, Output 2 (middle curve), and Output 3 (right curve) outputs. Thus, permanent readouts of inflammatory conditions encountered by probiotic bacteria can be recorded in DNA.
• Fig. 3 shows three different biosensing circuits expressing GFP for detecting H 2 0 2 levels were constructed in E. coli using two different promoters (oxySp and katGp) combined with three different ribosome binding sites (0033, 0031, 0029). The resulting circuit designs yield two different input-output transfer functions that have different thresholds and sensitivities for sensing H 2 0 2 levels.
• Figs. 4A-4B show curcumin production in E. coli.
• Fig. 4A shows the production of curcumin from ferulic acid requires expression of four heterologous enzymes.
• Fig. 4B shows a gene circuit for inflammation-inducible curcumin production.
• curcuminoid synthase (CUS) enzyme needed for the last conversion step (feruloyl-CoA to curcumin) is placed under regulation by inflammation sensors, for example those described in Figs. 2A- 2C.
• the disclosure relates to the use of probiotic bacteria as non-invasive sensors of inflammation and producers of localized anti-inflammatory compounds to treat inflammatory bowel disease (IBD).
• IBD inflammatory bowel disease
• probiotics can be consumed orally in order to diagnose and treat IBD as they transit through the gut.
• engineered probiotics can be recovered from stool and interrogated to recover information on the conditions they encountered during their transit through the gut.
• the disclosure relates to a recombinant probiotic cell comprising a sensor circuit, comprising: (a) a first promoter operably linked to a nucleic acid encoding a regulatory protein responsive to an input signal; (b) a second promoter responsive to the regulatory protein and operably linked to a nucleic acid encoding a first output protein, wherein activity of the second promoter is altered when bound by the regulatory protein; (c) an output molecule operably linked to a third promoter, wherein the output molecule or the third promoter is flanked by a first set of regulatory sequences, wherein the first set of regulatory sequences interacts with the first output protein to unlink the output molecule from the third promoter; (d) a fourth promoter responsive to the regulatory protein and operably linked to a nucleic acid encoding a second output protein, wherein activity of the fourth promoter is altered when bound by the regulatory protein; and, optionally, (e) a second output molecule flanked by a second
• probiotic cells comprising sensor circuits.
• probiotic refers to live micro-organisms which, when administered in adequate amounts, confer a health benefit on the host to which they are administered.
• E. coli Nissle 1917 bacteria were used to successfully treat an outbreak of shigellosis during World War I.
• probiotic organisms examples include bacteria ⁇ Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus reuteri ATCC 55730, Bifidobacterium longum, Bacillus coagulans, and Escherichia coli Nissle 1917 (EcN)) and fungi ⁇ e.g. Saccharomyces cerevisiae, Saccharomyces boulardii, Saccharomyces pastoriamus, Saccharomyces batanus).
• bacteria ⁇ Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus reuteri ATCC 55730, Bifidobacterium longum, Bacillus coagulans, and Escherichia coli Nissle 1917 (EcN)
• fungi ⁇ e.g
• probiotic cells of the present disclosure are anaerobic bacterial cells (e.g., cells that do not require oxygen for growth).
• Anaerobic bacterial cells include facultative anaerobic cells such as, for example, Escherichia coli and Lactobacillus sp..
• the probiotic cell comprising a sensor circuit is an E. coli cell.
• the E. coli cell is an E. coli Nissle 1917 (EcN) cell.
• probiotic cell of the present disclosure is a yeast cell.
• the yeast cell is a Saccharomyces boulardii cell.
• recombinant cell refers to a cell that has been engineered through genetic recombination to comprise nucleic acids that are not naturally be present in said cell.
• a recombinant cell contains an exogenous nucleic acid or a nucleic acid that does not occur in nature ⁇ e.g., sensor circuit of the present disclosure).
• a recombinant cell contains an exogenous independently replicating nucleic acid ⁇ e.g., components of analog signal processing circuits present on an episomal vector).
• a recombinant cell is produced by introducing a foreign or exogenous nucleic acid into a cell.
• a nucleic acid may be introduced into a cell by conventional methods, such as, for example, electroporation ⁇ see, e.g., Heiser W.C. Transcription Factor Protocols: Methods in
• a cell is modified to overexpress an endogenous protein of interest (e.g. , via introducing or modifying a promoter or other regulatory element near the endogenous gene that encodes the protein of interest to increase its expression level).
• a cell is modified by mutagenesis.
• a cell is modified by introducing an engineered nucleic acid into the cell in order to produce a genetic change of interest (e.g., via insertion or homologous recombination).
• a cell contains a gene deletion.
• Analog signal processing circuits of the present disclosure may be transiently expressed or stably expressed.
• Transient cell expression refers to expression by a cell of a nucleic acid that is not integrated into the nuclear genome of the cell.
• stable cell expression refers to expression by a cell of a nucleic acid that remains in the nuclear genome of the cell and its daughter cells.
• a cell is co-transfected with a marker gene and an exogenous nucleic acid (e.g. , an analog signal processing circuit or component thereof) that is intended for stable expression in the cell.
• the marker gene gives the cell some selectable advantage (e.g., resistance to a toxin, antibiotic, or other factor).
• marker genes and selection agents for use in accordance with the present disclosure include, without limitation, dihydrofolate reductase with methotrexate, glutamine synthetase with methionine sulphoximine, hygromycin phosphotransferase with hygromycin, puromycin N-acetyltransferase with puromycin, and neomycin phosphotransferase with Geneticin, also known as G418.
• Other marker genes/selection agents are contemplated herein.
• the disclosure relates to recombinant probiotic cells comprising a sensor circuit.
• a “sensor circuit” refers to a genetic circuit used to detect a biological signal, for example an inflammatory marker.
• Biological signals are often present in dynamic concentration gradients and in some cases it is desirable to convert a gradient of input signal into discreet expression of a molecule or molecules (e.g. via the application of analog to digital logic). Therefore, in some embodiments, the sensor circuit is a biological analog signal processing circuit.
• biological analog signal processing circuits see U.S. Serial No. 62/095,318 (Attorney Docket No.
• Analog signal processing circuits of the present disclosure comprise promoters responsive to an input signal and operably linked to a nucleic acid encoding an output molecule.
• a "promoter” is a control region of a nucleic acid at which initiation and rate of transcription of the remainder of a nucleic acid are controlled.
• a promoter may also contain sub-regions at which regulatory proteins and molecules, such as transcription factors, bind. Promoters of the present disclosure may be constitutive, inducible, activatable, repressible, tissue-specific or any combination thereof.
• a promoter drives expression or drives transcription of the nucleic acid that it regulates.
• a promoter is considered to be “operably linked” when it is in a correct functional location and orientation in relation to the nucleic acid it regulates to control (“drive”) transcriptional initiation and/or expression of that nucleic acid.
• a promoter is considered "responsive" to an input signal if the input signal modulates the function of the promoter, indirectly or directly.
• an input signal may positively modulate a promoter such that the promoter activates, or increases (e.g., by a certain percentage or degree), transcription of a nucleic acid to which it is operably linked.
• an input signal may negatively modulate a promoter such that the promoter is prevented from activating or inhibits, or decreases, transcription of a nucleic acid to which it is operably linked.
• An input signal may modulate the function of the promoter directly by binding to the promoter or by acting on the promoter without an intermediate signal.
• the oxyR protein modulates the oxyR promoter by binding to a region of the oxyR promoter.
• the oxyR protein is herein considered an input signal that directly modulates the oxyR promoter.
• an input signal is considered to modulate the function of a promoter indirectly if the input signal modulates the promoter via an intermediate signal.
• hydrogen peroxide ( ⁇ 2 0 2 ) modulates (e.g. , activates) the oxyR protein, which, in turn, modulates (e.g., activates) the oxyR promoter.
• ⁇ 2 0 2 is herein considered an input signal that indirectly modulates the oxyR promoter.
• an “input signal” refers to any chemical (e.g., small molecule) or non-chemical (e.g., light or heat) signal in a cell, or to which the cell is exposed, that modulates, directly or indirectly, a component (e.g., a promoter) of an analog signal processing circuit.
• an input signal is a biomolecule that modulates the function of a promoter (referred to as direct modulation), or is a signal that modulates a biomolecule, which then modulates the function of the promoter (referred to as indirect modulation).
• biomolecule is any molecule that is produced in a live cell, e.g., endogenously or via recombinant-based expression.
• H 2 0 2 and Nitric oxide (NO) are considered input signals that indirectly modulate the oxyR promoter and nir, hep, nrfA, nasD, ytfE, yeaR, nnrS and norV promoters, respectively, and, in turn, expression of output molecules.
• oxyR and NorR or NsrR proteins are themselves considered input signals because they directly modulate transcription of output molecules by binding to oxyR promoter(s) (for example oxyR, katGp oxySp, ahpSp, HemHp, ahpCp2, dsbGp, uofp, dpsp, grxAp, ybjCp, hepp, ychFp, sufAp, flup, mntHp, trxCp, gorp, yhjAp, oxyRp, gntPp, uxuAp, fhuFp, katGp) or nir, or hep, or nrfA, or nasD, or ytfE, or yeaR, or nnrS or norV, respectively .
• oxyR promoter(s) for example oxyR, katGp oxySp, ah
• an input signal is constitutively expressed in a cell.
• the input signal is oxyR protein.
• the input signal is NorR or NsrR protein.
• the disclosure relates to sensor circuits responsive to inflammatory marker input signals.
• inflammatory marker relates to any chemical or biological indicator of an inflammatory immune response. Examples of inflammatory markers include but are not limited to IL-1, IL-6, IL-18, TNF-a, IFN- ⁇ , H 2 0 2 , NO, blood, Calprotectin, Lactoferrin, other molecules associated with neutrophil invasion into the gut lumen.
• IBD inflammatory bowel disease
• IBD inflammatory bowel disease
• inflammatory bowel disease refers to a heterogeneous group of chronic inflammatory disorders of the gastrointestinal tract that includes Crohn's disease (CD) and ulcerative colitis (UC).
• Combinations of input signals are also contemplated, for example a recombinant probiotic cell comprising a sensor circuit responsive to two or more of the input signals selected from the group consisting of H 2 O 2 , NO, IL-6, IL-18, TNFa, Blood, Calprotectin, Lactoferrin.
• Recombinases are enzymes that mediate site- specific recombination by binding to nucleic acids via conserved recognition sites and mediating at least one of the following forms of DNA rearrangement: integration, excision/resolution and/or inversion.
• Recombinases are generally classified into two families of proteins, tyrosine recombinases (YR) and serine recombinases (SR). However, recombinases may also be classified according to their directionality (i.e. bidirectional or unidirectional).
• unidirectional recombinases include but are not limited to Bxbl, PhiC31, TP901, HK022, HP1, R4, Intl, Int2, Int3, Int4, Int5, Int6, Int7, Int8, Int9, IntlO, Intl l, Intl2, Intl3, Intl4, Intl5, Intl6, Intl7, Intl8, Intl9, Int20, Int21, Int22, Int23, Int24, Int25, Int26, Int27, Int28, Int29, Int30, Int31, Int32, Int33, and Int34. Further unidirectional recombinases may be identified using the methods disclosed in Yang et al., Nature Methods, October 2014; 11(12), pp.1261-1266, herein incorporated by reference in its entirety.
• the circuit(s) comprise at least one unidirectional recombinase, wherein the recognition sites flanking a nucleic acid sequence are operable with the at least one unidirectional recombinase.
• the circuit(s) comprise two or more unidirectional recombinases.
• biological signal processing circuits that are reversible.
• Reversible biological signal processing circuits allow the expression of an output molecule to be turned on and off, for example via the use of a "reset switch" or a second circuit that reverses the activity of an activated regulatory protein.
• the biological signal processing circuit comprises at least one bidirectional recombinase. Bidirectional recombinases bind to identical recognition sites and therefore mediate reversible
• bidirectional recombinases include, but are not limited to, Cre, FLP, R, IntA, Tn3 resolvase, Hin invertase and Gin invertase.
• the output molecule is flanked by at least one bidirectional recombinase recognition site.
• the bidirectional recombinase recognition sites flanking an output molecule are the same.
• the bidirectional recombinase recognition sites flanking an output molecule are different.
• Non-limiting examples of identical recognition sites for bidirectional recombinases include loxP, FRT and RS recognition sites.
• Sensor circuits, and components thereof, of the disclosure can be "tuned” by promoter modification such that the affinity of a promoter for a regulatory protein differs relative to the affinity of another promoter for the same regulatory protein. Further tuning of analog signal processing circuits is contemplated herein.
• a "regulatory sequence” may be included in a circuit to further regulate transcription, translation or degradation of an output molecule or regulatory protein.
• regulatory sequences include, without limitation, ribosomal binding sites, riboswitches, ribozymes, guide RNA binding sites, microRNA binding sites, toe-hold switches, cis-repressing RNAs, siRNA binding sites, protease target sites, recombinase recognition sites and transcriptional terminator sites.
• the biological analog signal processing circuit comprises two or more different regulatory sequences.
• the regulatory sequences regulate the transcription and/or translation of an output molecule.
• the regulatory sequences regulate the operable linkage of a promoter to a nucleic acid sequence encoding an output protein.
• a first set of regulatory sequences regulates the transcription and/or translation of an output molecule and a second set of regulatory sequences regulates the operable linkage of a promoter to a nucleic acid sequence encoding an output protein.
• Tuning also can be achieved by changing the affinity of RNA polymerase for the promoter, and thus the strength of the promoter. For example, one or more mutations are made in the - 10 region of the promoter. By changing the promoter strength (and thus transcription rate of the recombinase), digital switches are obtained (with regards to an input, such as H202) at different concentrations.
• Sensor circuits of the present disclosure generate a response in the form of an output molecule.
• An "output molecule” refers to any detectable molecule under the control of (e.g., produced in response to) an input signal.
• Output 1, Output 2 and Output 3 are output molecules produced in response to activation of a promoter driving expression of a recombinase gene (Rec. 1, Rec. 2 and Rec. 3) by an inflammatory marker.
• the expression level of an output molecule in some embodiments, in some
• the expression level of an output protein under the control of a modified promoter having reduced affinity for a regulatory protein may be less than the expression level of an output molecule under the control of the unmodified promoter.
• the expression level of an output molecule under the control of a modified promoter having reduced affinity for a regulatory protein may be less than the expression level of an output molecule under the control of a modified promoter having an even greater reduction in its affinity for the same regulatory protein.
• output molecules include, without limitation, proteins and nucleic acids.
• output molecules are detectable. Detectable output molecules are useful for the formation of DNA memory.
• an input signal can activate expression of a recombinase, which irreversibly flips a specific stretch of DNA, thus creating a stable memory of events that can be read out via reporter assays (e.g., fluorescent proteins, colorimetric assays, luciferase), DNA sequencing, and/or PCR-based reactions.
• reporter assays e.g., fluorescent proteins, colorimetric assays, luciferase
• therapeutic molecules contemplated herein include antibodies, single variable domains, scFv-fragments, 5-aminosalicylates, corticosteroids, immunosuppressive agents, antibiotics, and RNAi molecules or guideRNA molecules targeting inflammatory pathways, antibodies/antibody fragments against interleukins or communication molecules themselves (such as TNF-alpha or IL-16), as well as antibodies/antibody fragments against
• the disclosure relates to a method of treating an inflammatory bowel disease in a subject in need thereof, the method comprising administering to a subject in need thereof a probiotic cell comprising a sensor circuit as described herein.
• Administering the pharmaceutical composition of the present disclosure may be accomplished by any means known to the skilled artisan. Routes of administration include but are not limited to oral, parenteral, intravenous, intramuscular, intraperitoneal, intranasal, sublingual, intratracheal, inhalation, subcutaneous, ocular, vaginal, and rectal.
• the compounds can be formulated readily by combining the cell(s) with pharmaceutically acceptable carriers well known in the art.
• pharmaceutically acceptable carriers well known in the art.
• Such carriers enable the compounds of the present disclosure to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated.
• the probiotic cell is administered as part of a probiotic formulation, optionally as a component in a food product.
• the term "subject in need thereof refers to any animal that has signs or symptoms associated with, or is suspected of having, an inflammatory bowel disease.
• the subject is a mammal.
• the subject is a human, non-human primate, equine, porcine, canine, or feline subject.
• the sensor circuit is a biological analog signal processing circuit.
• the input signal is hydrogen peroxide (H202).
• the input signal is nitric oxide (NO).
• the input molecule is an inflammatory cytokine, optionally IL-6, IL-18, or TNFa.
• the input molecule is a molecule produced by neutrophils, such as calprotectin or lactoferrin.
• the input signal is blood
• the first and/or second output molecule is a therapeutic molecule.
• the therapeutic molecule is an anti-inflammatory molecule.
• the anti-inflammatory molecule is a cytokine, optionally IL-10.
• the antiinflammatory molecule is curcumin.
• the antiinflammatory molecule is an antibody or antibody fragment.
• the sensor circuit further comprises a second output molecule.
• the second output molecule is the same as the first output molecule.
• Some aspects of the disclosure relate to a method of diagnosing an inflammatory bowel disease in a subject, the method comprising: a) administering to a subject a probiotic cell as described herein; b) obtaining a biological sample from the subject of (a); c) detecting the expression of the at least one output molecule in the biological sample; and, d) diagnosing the subject as having an inflammatory bowel disease or a flare-up of inflammatory bowel diseases.
• biological sample refers to a specimen obtained from a subject from which inflammatory markers can be identified.
• biological samples include but are not limited to tissue, blood, saliva, urine and fecal samples.
• the biological sample is a fecal sample.
• the expression of the output molecule is detected in vitro.
• the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
• the method further comprises administering an agent useful for treatment of IBD to the subject.
• a recombinant probiotic cell comprising: a sensor circuit, comprising: (a) a first promoter operably linked to a nucleic acid encoding a regulatory protein responsive to an input signal; (b) a second promoter responsive to the regulatory protein and operably linked to a nucleic acid encoding a first output protein, wherein activity of the second promoter is altered when bound by the regulatory protein; (c) an output molecule operably linked to a third promoter, wherein the output molecule or the third promoter is flanked by a first set of regulatory sequences, wherein the first set of regulatory sequences interacts with the first output protein to unlink the output molecule from the third promoter; (d) a fourth promoter responsive to the regulatory protein and operably linked to a nucleic acid encoding a second output protein, wherein activity of the fourth promoter is altered when bound by the regulatory protein; and, optionally, (e) a second output molecule flanked by a second set of regulatory sequences, wherein the second set
• the promoter of (b) and/or (d) is a promoter selected from the group consisting of oxyR, oxySp, katGp, nir, hep, nrf A, nasD, ytfE, yeaR, nnrS and norV that comprises a modification that alters the binding affinity of a transcription factor or RNA polymerase for a promoter selected from the group consisting of oxyR, nir, hep, nrfA, nasD, ytfE, yeaR, nnrS and norV of (b), relative to a similar unmodified promoter.
• the promoter of (b) and/or (d) is a promoter selected from the group consisting of oxyR, oxySp, katGp, nir, hep, nrf A, nasD, ytfE, yeaR, nnrS and norV that is a naturally occurring promoter.
• 32. A method of treating an inflammatory bowel disease in a subject in need thereof, the method comprising administering to a subject in need thereof the probiotic cell of any one of paragraphs 1 to 31.
• a method of diagnosing an inflammatory bowel disease in a subject comprising: (a) administering to a subject the probiotic cell of any one of paragraphs 1 to 16; (b) obtaining a biological sample from the subject of (a); (c) detecting the expression of the at least one output molecule in the biological sample; and (d) diagnosing the subject as having an inflammatory bowel disease.
• a recombinant probiotic cell comprising: a sensor circuit, comprising: (a) a first promoter operably linked to a nucleic acid encoding a regulatory protein responsive to an input signal; and (b) a second promoter responsive to the regulatory protein and operably linked to a nucleic acid encoding a first output protein, wherein activity of the second promoter is altered when bound by the regulatory protein.
• the modification is a nucleic acid mutation.
• sequence element is a modified ribosomal binding site comprising a modification that alters the binding affinity of a ribosome for the modified ribosomal binding site, relative to a similar unmodified ribosomal binding site.
• the promoter of (b) is a promoter selected from the group consisting of oxyR, oxySp, katGp, nir, hep, nrfA, nasD, ytfE, yeaR, nnrS and norV that comprises a modification that alters the binding affinity of a transcription factor or RNA polymerase for a promoter selected from the group consisting of oxyR, nir, hep, nrfA, nasD, ytfE, yeaR, nnrS and norV of (b), relative to a similar unmodified promoter.
• the promoter of (b) is a promoter selected from the group consisting of oxyR, oxySp, katGp, nir, hep, nrfA, nasD, ytfE, yeaR, nnrS and norV that is a naturally occurring promoter.
• the recombinant probiotic cell of paragraph 71, wherein the antiinflammatory molecule is a cytokine, optionally IL-10.
• the antiinflammatory molecule is curcuminoid synthase (CUS) that converts feruloyl-CoA to curcumin.
• CCS curcuminoid synthase
• nucleic acids that encode 4-coumarate CoA ligase and acetyl-CoA carboxylase, which nucleic acids optionally are on one or more vectors.
• nucleic acids that encode acetyl-CoA carboxylase are AccBc and DtsRl.
• nucleic acids that encode 4-coumarate CoA ligase and acetyl-CoA carboxylase are operably linked to constitutive promoters.
• a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering to a subject in need thereof the probiotic cell of any one of claims54 to 79.
• a sensor circuit comprising: (a) a first promoter operably linked to a nucleic acid encoding a regulatory protein responsive to an input signal; (b) a second promoter responsive to the regulatory protein and operably linked to a nucleic acid encoding a first output protein, wherein the second promoter is a nir, hep, nrfA, nasD, ytfE, yeaR, nnrS or norV promoter, and wherein activity of the second promoter is altered when bound by the regulatory protein; and (c) an output molecule flanked by a first set of regulatory sequences, wherein the first set of regulatory sequences interacts with the first output protein to operably link the output molecule to a third promoter.
• the recombinant cell of paragraph 83 further comprising: (e) a second output molecule flanked by a second set of regulatory sequences, wherein the second set of regulatory sequences interacts with the second output protein to operably link the second output molecule to a fifth promoter.
• the present disclosure is related, in part, to the engineering of a suite of probiotic bacteria as in vivo sensors for inflammation and localized therapeutics. Although many powerful synthetic gene circuits have been described in the last decade, few have been applied to study and manipulate human diseases.
• the probiotic cells described herein are useful for studying inflammation in both healthy and diseased environments, allowing for the identification of the timing and concentration of key molecules that initiate and contribute to the development of IBD and the design of diagnostics for early detection of IBD flares.
• probiotic cells comprising diagnostic sensors are also engineered to express anti-inflammatory therapeutics on-demand, thus resulting in intelligent drugs that make decisions about the timing, dosage, and location of IBD therapeutics.
• Prior work on probiotics has utilized constitutive production of anti-inflammatory drugs, but these have not shown good efficacy in clinical trials.
• probiotic bacteria such as E. coli Nissle 1917
• the probiotic cells are engineered to comprise a suite of orthogonal recombinases that are expressed under multiple independent circuits and that are induced by different levels of inflammation.
• the expression of Recombinase 1 is induced when the inflammation sensor exceeds a low threshold
• the expression of Recombinase 2 is induced when the inflammation sensor exceeds a medium threshold
• expression of Recombinase 3 is induced when the inflammation sensor exceeds a high threshold.
• EcFpFB or iLOV (22), that does not require 0 2 for maturation, as an output molecule on the same plasmid.
• NO sensor circuits are transformed into E. coli MG1655-Pro, a strain that expresses Lacl from the genome, by inducing with increasing concentrations of IPTG and NO-generating molecules, such as sodium nitroprusside or diethylenetriamine/nitric oxide.
• the NO sensing circuit is endogenously designed to function anaerobically or micro-aerobically.
• Engineered probiotic cells with inflammation sensor circuits expressing antiinflammatory protein and/or anti-inflammatory small molecules are constructed.
• useful output molecules include the cytokine IL-10, anti-TNFa antibodies, antibody fragments, and the small molecule curcumin.
• Sensor circuit designs are inserted into probiotic bacteria and tested in vitro by inducing with various concentrations of reactive oxygen species and measuring the time response and the titers of the resulting antiinflammatory compounds.
• OxyR a positive regulator of hydrogen peroxide- inducible genes in Escherichia coli and Salmonella typhimurium, is homologous to a family of bacteria regulatory proteins. PNAS, 86 (1989), 3484.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Zoology (AREA)
• Epidemiology (AREA)
• Microbiology (AREA)
• Organic Chemistry (AREA)
• Biotechnology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biochemistry (AREA)
• Wood Science & Technology (AREA)
• General Engineering & Computer Science (AREA)
• Physics & Mathematics (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Mycology (AREA)
• Gastroenterology & Hepatology (AREA)
• Biophysics (AREA)
• Cell Biology (AREA)
• Plant Pathology (AREA)
• Analytical Chemistry (AREA)
• Food Science & Technology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Nutrition Science (AREA)
• Medical Informatics (AREA)
• Endocrinology (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=55273522

Family Applications (1)

Country Status (6)

Cited By (6)

Families Citing this family (5)

Citations (1)

Family Cites Families (1)

• 2015
  • 2015-12-22 US US15/535,831 patent/US20170360850A1/en not_active Abandoned
  • 2015-12-22 WO PCT/US2015/067435 patent/WO2016106343A1/en not_active Ceased
  • 2015-12-22 EP EP15831026.8A patent/EP3237437A1/en not_active Withdrawn
  • 2015-12-22 JP JP2017534611A patent/JP2018501797A/ja active Pending
  • 2015-12-22 CA CA2971876A patent/CA2971876A1/en not_active Abandoned
  • 2015-12-22 AU AU2015369627A patent/AU2015369627A1/en not_active Abandoned

Patent Citations (1)

Non-Patent Citations (35)

Also Published As

Similar Documents

Legal Events